2nd China COVID-19 vaccine passes PH panel review | Inquirer News

2nd China COVID-19 vaccine passes PH panel review

By: - Reporter / @DYGalvezINQ
/ 02:14 PM November 27, 2020
Clover Biopharmaceuticals

SCB-2019 (S-Trimer COVID-19 Vaccine) SCB-2019 is a recombinant subunit vaccine candidate for COVID-19. Utilizing its patented Trimer-Tag© technology, Clover has produced a S-Trimer subunit vaccine candidate that resembles the native trimeric viral spike via mammalian cell-culture production system. Image from Clover Biopharmaceuticals website

MANILA, Philippines — A COVID-19 vaccine from another Chinese drugmaker passed the evaluation of the country’s vaccine experts panel, making it the second Chinese COVID-19 vaccine to advance in the application for a clinical trial.

Dr. Jaime Montoya, executive director of the Department of Science and Technology’s Council for Health Research and Development, said Clover Biopharmaceuticals from China has passed the technical review of the Philippines’ vaccine expert panel.

ADVERTISEMENT

Their application was then submitted to the Ethics Review Board for evaluation and the Food and Drug Administration before it can conduct a clinical trial in the country.

The first vaccine to pass the vaccine experts panel is China’s Sinovac Biotech, whose application was approved by the panel sometime in October.

FEATURED STORIES

“Ang Sinovac ay nakatapos na ng technical review. Mayroong isang kumpanya na nakatapos na ng technical review. Ito ‘yung Clover Biopharmaceuticals,” Montoya said in an online forum.

(Sinovac is already done with its technical review by the vaccine experts panel. Another company, Clover Biopharmaceuticals, is also finished.)

“So dalawa ‘yan at ‘yan ay pinasa na sa Ethics Review Board,” he added.

(So that’s two firms already and both have submitted their application to the Ethics Review Board.)

If everything goes smoothly, Montoya said both firms could start their clinical trials by late December or early January.

The Philippines is in talks with 17 drugmakers for a potential COVID-19 vaccine, Montoya said, five of which have already submitted their application to conduct a clinical trial in the country.

EDV
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: China, Clover, COVID-19, COVID-19 Vaccine, Sinovac, vaccine experts panel, vaccine panel review
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.



© Copyright 1997-2023 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.